Skip to main content
SCYX
NASDAQ Life Sciences

SCYNEXIS Executes 1-for-8 Reverse Stock Split for Nasdaq Compliance

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$0.705
Mkt Cap
$56.007M
52W Low
$0.565
52W High
$1.31
52W Position info
25% above low
Off High info
46% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

SCYX sits 25% above its 52-week low of $0.565.

Summary

SCYNEXIS completed a 1-for-8 reverse stock split to meet Nasdaq listing requirements, with split-adjusted trading beginning June 1, 2026. The company also reduced its authorized shares, avoiding a previously proposed larger increase.


Key Events · Corporate Governance and Compliance · SCYX

  • Reverse Stock Split Executed

    A 1-for-8 reverse stock split of common stock became effective on May 29, 2026, consolidating shares and increasing the per-share price.

  • Nasdaq Trading Adjustment

    Shares will begin trading on a split-adjusted basis on the Nasdaq Capital Market starting June 1, 2026, under the existing ticker symbol SCYX.

  • Compliance and Delisting Avoidance

    This action is crucial for the company to meet Nasdaq's minimum bid price requirement, thereby preventing potential delisting.

  • Authorized Share Reduction

    The total number of authorized common shares was reduced from 150,000,000 to 18,750,000 (post-split), effectively maintaining the pre-split equivalent of 150,000,000 shares and avoiding a previously proposed increase to 300,000,000 shares.


Analysis · SCYX · Life Sciences

SCYNEXIS has finalized and executed a 1-for-8 reverse stock split, a critical step to increase its share price and regain compliance with Nasdaq's minimum bid price requirement. This action prevents potential delisting, which is a significant risk for the company. Additionally, the company reduced its authorized shares to an equivalent of 150 million pre-split, avoiding a previously proposed increase to 300 million, which mitigates future dilution concerns for shareholders.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, SCYX was trading at $0.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $56M. The 52-week trading range was $0.57 to $1.31. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SCYX - Latest Insights

SCYX
Nov 05, 2026, 8:01 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $3.84
Real-time Price: $2.38 info
Change: -$1.46 (-38%) info
Market Cap: $23.689M info
SCYX
Oct 06, 2026, 7:53 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $5.18
Real-time Price: $2.38 info
Change: -$2.80 (-54%) info
Market Cap: $23.689M info
SCYX
Sep 28, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.71
Real-time Price: $2.38 info
Change: -$2.33 (-50%) info
Market Cap: $23.689M info
SCYX
Sep 28, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $6.46
Real-time Price: $2.38 info
Change: -$4.08 (-63%) info
Market Cap: $23.689M info
SCYX
Aug 10, 2026, 4:30 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $5.27
Real-time Price: $2.38 info
Change: -$2.89 (-55%) info
Market Cap: $23.689M info